Full-Time
Senior I Stat Prog Lead
Updated on 9/3/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
High Wycombe, UK
In Person
 Biology & Biotech (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- Advanced knowledge of statistical programming methods, languages and data structures and capabilities in leading analysis and reporting activities and programming teams in accordance to departmental processes and procedures.
- Accountable for Statistical Programming team delivery for one or more clinical projects generally of low to medium complexity, scope or criticality.
- Coordinates and oversees programming team activities and provides technical and project specific guidance to programming team members to ensure quality and on-time statistical programming deliverables in compliance with departmental processes and procedures.
- Develops detailed programming strategy, specifications and plans the programming deliverables for a one or more clinical projects. May act as a section lead of programming activities supporting a clinical program, compound or submission.
- Performs comprehensive review of, and provides input into, project requirements and documentation.
- Collaborates effectively with statistical programming and cross-functional team members and counterparts to achieve project goals.
- Designs and develops programs in support of complex clinical data analysis and reporting activities.
- Applies technical and analytical expertise to develop and implement solutions for use on clinical projects leading to increased efficiency and quality.
- May contribute to or lead others in an area of expertise that results in solutions increasing the efficiency and quality of deliverables across multiple projects.
- Advanced Analytics
- Biostatistics
- Clinical Trials
- Collaboration
- Consulting
- Critical Thinking
- Data Privacy Standards
- Data Quality
- Data Savvy
- Digital Fluency
- Good Clinical Practice (GCP)
- Quality Assurance (QA)
- Report Writing
- Standard Operating Procedure (SOP)
- Statistical Analysis Systems (SAS) Programming
- Statistics
- Systems Development
- Technologically Savvy
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
- IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
- Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.
What critics are saying
- The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
- CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
- Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.
What makes Johnson & Johnson unique
- J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
- Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
- Its oncology and immunology franchises offset Stelara’s erosion.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -3%Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.
AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.
Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.